Trials / Recruiting
RecruitingNCT06588153
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prolia® | Subcutaneous (SC) injection in pre-filled syringe. |
Timeline
- Start date
- 2025-05-24
- Primary completion
- 2027-05-24
- Completion
- 2027-05-24
- First posted
- 2024-09-19
- Last updated
- 2026-03-25
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06588153. Inclusion in this directory is not an endorsement.